← FDA DRUG APPROVALS

FDA NDA · NDA021409

SINGULAIR

montelukast sodium

Sponsor: ORGANON

APPLICATION
NDA021409
TYPE
NDA
ORIGINAL APPROVAL
2002-07-26
LATEST ACTION
2021-02-22
ROUTE
ORAL
DOSAGE FORM
GRANULE
MARKETING STATUS
Discontinued

Products

SINGULAIR · ReferenceDiscontinued
MONTELUKAST SODIUM EQ 4MG BASE/PACKET · GRANULE · ORAL

Approval history

2021-02-22Labeling · Supplement 52 · standardLetterAP
2020-04-29Labeling · Supplement 51 · standardLetterAP
2019-08-09Labeling · Supplement 50 · standardLetterAP
2018-12-21Labeling · Supplement 48 · standardLabelAP
2018-12-21Labeling · Supplement 49 · standardLabelAP
2016-12-13Labeling · Supplement 47 · standardLetterAP
2014-11-26Labeling · Supplement 45 · standardLetterAP
2013-12-30Labeling · Supplement 43 · standardLetterAP
2013-03-21Labeling · Supplement 42 · standardLabelAP
2012-10-18Labeling · Supplement 39 · unknownLetterAP
2012-09-27Labeling · Supplement 40 · unknownLetterAP
2012-03-26Efficacy · Supplement 36 · standardLetterAP
2011-12-16Labeling · Supplement 37 · unknownLetterAP
2011-04-27Labeling · Supplement 34 · unknownLabelAP
2010-08-10Labeling · Supplement 31 · unknownLetterAP
2010-04-26Labeling · Supplement 29 · standardLabelAP
2009-08-19Labeling · Supplement 28 · standardLabelAP
2009-01-27Labeling · Supplement 27 · standardLabelAP
2008-04-24Labeling · Supplement 26 · standardLetterAP
2008-04-21Labeling · Supplement 25 · standardLabelAP
2008-03-07Labeling · Supplement 23 · standardLetterAP
2007-04-13Efficacy · Supplement 16 · unknownLabelAP
2006-12-08Labeling · Supplement 19 · standardLabelAP
2006-05-19Labeling · Supplement 18 · standardLabelAP
2005-11-30Efficacy · Supplement 14 · unknownLetterAP
2005-07-27Efficacy · Supplement 12 · unknownLetterAP
2005-06-27Labeling · Supplement 17 · standardLabelAP
2005-05-26Labeling · Supplement 15 · standardLabelAP
2004-12-29Labeling · Supplement 11 · standardAP
2004-11-15Labeling · Supplement 10 · standardLetterAP
2003-12-19Labeling · Supplement 7 · standardLetterAP
2003-10-02Labeling · Supplement 5 · standardLetterAP
2002-12-31Efficacy · Supplement 3 · unknownLetterAP
2002-07-26Type 3 - New Dosage Form · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →